Herpes simplex virus antiviral drug resistance - Current trends and future prospects

Journal of Clinical Virology

Volumn 21, Issue 3, 2001, Pages 261-269

  Field, H J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antiviral drug; Future prospects; Herpes

Indexed keywords

ACICLOVIR; DNA POLYMERASE; THYMIDINE KINASE;

AUTORADIOGRAPHY; CELL CULTURE; CONFERENCE PAPER; DRUG RESISTANCE; FLOW CYTOMETRY; GENE LOCUS; GENOTYPE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; PATHOGENICITY; PRIORITY JOURNAL; TECHNIQUE; VIRUS CULTURE; VIRUS MUTATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; FORECASTING; HERPES SIMPLEX; HUMANS; SIMPLEXVIRUS;

EID: 0034980063     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(00)00169-4     Document Type: Conference Paper

References (56)

1. Viral resistance in clinical practice: summary of 5 years experience with acyclovir
2. Clinical and laboratory experience with acyclovir-resistant herpes simplex viruses
3. Predicting and preventing the emergence of antiviral drug resistance
4. Surveillance for resistant herpes simplex virus type 1 (HSV-1): a collaborative survey in the US of the general population with recurrent herpes labialis
5. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern
6. Analysis of the thyn-ddine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses
7. Survey of resistance of herpes simplex virus to acyclovir in North-west England
8. Antiviral drug resistance in herpes simplex virus
9. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1
10. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir
11. Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents
12. Altered substrate specificity of herpes simplex virus thymidine kinase confers ayclovir-resistance
13. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide
14. Oral famciclovir for the suppression of recurrent genital herpes. a randomized controlled trial
15. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center
16. Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy
17. Famciclovir - Origins, progress and prospects
18. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene
19. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo
20. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir
21. Early therapy with valaciclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency
22. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice
23. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients
24. Acyclovir prophylaxis for herpes simplex virus infection
25. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized regimen-comparative trial
26. Nucleoside pools of acyclovir-treated herpes simplex type 1-infected cells
27. Multiplicity dependence of sensitivity of herpes simplex virus isolates to antiviral compounds
28. Plaque inhibition test for detection of inhibitors of DNA viruses
29. Analysis of herpes simplex virus isolated from patients with recurrent herpes keratitis exhibiting 'treatment resistance' to 5-iodo-2′-deoxyurindine
30. Recurrent acyclovir-resistant herpes simplex virus in an imunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis?
31. Recurrent acyclovirresistant genital herpes in an immunocompetent patient
32. Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains
33. Related functional domains in virus DNA polymerases
34. Virus drug-resistance: mechanisms and consequences
35. Standardisation of a microplate in situ ELISA (MISE-test) for the susceptibility testing of herpes simplex virus to acyclovir
36. Extended acyclovir therapy for herpes genitalis: changes in virus sensitivity and strain variation
37. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo
38. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates
39. A colorimetric assay for the measurement of the sensitivy of herpes simplex virus to antiviral agents
40. Antiviral drug susceptibility assays: going with the flow
41. Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir and forscarnet
42. Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants
43. Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes - a randomized, double-blind multicenter trial
44. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome
45. A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates
46. An acyclovir-resistant strain of herpes simplex virus type-2 which is highly virulent for mice
47. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion?
48. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir
49. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci
50. Some biologic aspects of herpesvirus-cell interactions in the presence of 5-iodo,2-deoxyuridine (IDU)
51. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir
52. Sensitivity of HSV strains isolated before and after treatement with acyclovir
53. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant thymidine kinase-deficient herpes simplex virus
54. A rapid assay to screen for drug-resistant herpes simplex virus
55. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double blind trial